
Stimulating insulin secretion from the pancreas when blood glucose rises
Inhibiting glucagon release, which helps prevent excess glucose production by the liver
Slowing gastric emptying, leading to prolonged digestion and steadier blood sugar levels

Available as Victoza (for diabetes) and Saxenda (for weight management)
Available as Ozempic (for diabetes) and Wegovy (for weight management)
Available as Mounjaro (for diabetes and weight management)
GLP-1 agonists help manage blood glucose levels by stimulating insulin production and limiting glucose output from the liver. They are often recommended when oral medications such as metformin are not sufficient in controlling blood sugar. Some GLP-1 agonists have demonstrated benefits in reducing the risk of cardiovascular events in individuals with type 2 diabetes and heart disease.
For individuals without diabetes, medications like Saxenda and Wegovy are approved specifically for weight loss. These GLP-1 agonists work by promoting satiety and curbing hunger, helping patients eat less without feeling deprived. Research has shown that patients using GLP-1 therapy alongside lifestyle changes can achieve significant and sustainable weight loss.
GLP-1 receptor agonists manage blood glucose by stimulating insulin release in response to meals and suppressing glucagon secretion. This mechanism helps lower post-meal blood sugar spikes and improves overall glycemic control. As the effect is glucose-dependent, the risk of hypoglycemia is much lower compared to many other diabetes treatments, making it a safer option for managing type 2 diabetes.
GLP-1 therapy is also highly effective in supporting sustainable weight loss. By slowing gastric emptying and increasing feelings of fullness, these medications reduce appetite, making it easier for patients to eat less and achieve their weight loss goals. Clinical evidence supports that drugs like liraglutide, semaglutide, and tirzepatide help individuals achieve meaningful weight loss and maintain it over time.



These medications stimulate both GLP-1 and GIP receptors, enhancing insulin release and appetite control more effectively than GLP-1 alone. The dual-action mechanism makes them an exciting advancement for managing metabolic disorders like obesity and type 2 diabetes.
GLP-1/glucagon co-agonists promote fat loss while maintaining muscle mass, making them a promising approach to improving weight management and metabolic health.

